



**STATEMENT BY MALAYSIA
150TH SESSION OF THE WHO'S EXECUTIVE BOARD
24 – 29 JANUARY 2022**

Agenda Item No. : 21.1

Title : Global strategy and plan of action on public health, innovation and intellectual property

Ref. Document : (EB150/36)

Thank you Chair,

1. Malaysia, via the Pharmaceutical Services Programme (PSP) has benefited from the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property since its implementation in 2008. To date, Malaysia, through National Pharmaceutical Regulatory Agency (NPRA), continues to be a member and active participant in networks devoted to the regulatory control of medicines, including the International Regulatory Cooperation for Herbal Medicines (IRCH), the National Control Laboratory Network for Biologics, and the Collaborative Procedure for Accelerated Registration (CPR) for prequalified products. These networks will significantly accelerate access to vaccines. They will serve as a platform for the confidential exchange of quality and technical information about vaccines (or other biological medicinal products) and the registration of prequalified products under the WHO Prequalification of Medicines Programme.

2. PSP in general also has attended every session of the WHO Fair Pricing Forum and continues to support the promotion of pharmaceutical product price transparency. Malaysia is currently engaging with relevant stakeholders to ensure fair prices and improve price transparency of medicines in the country. In addition, we are also participating in the Price Information Exchange for Selected Medicines in the Western Pacific Region (PIEMEDS) online platform, which aims to promote price transparency among contributing countries.
3. In light of these benefits, Malaysia strongly supports the notion of extending the duration of the plan of action beyond 2022 to ensure the ongoing action plan's continuance. Through the implementation of this plan, PSP has collaborated with regional and international counterparts to strengthen the regulatory control of medicinal products and improve global medicines pricing transparency to ensure the public's access to safe, efficacious, and high-quality medicinal products.
4. PSP in general also has attended every session of the WHO Fair Pricing Forum and continues to support the promotion of pharmaceutical product price transparency. Malaysia is currently engaging with relevant stakeholders to introduce Medicines Pricing Mechanism which will ensure fair prices and improve price transparency of medicines in the country, as well as to participate in the Price Information Exchange for Selected Medicines in the Western Pacific Region (PIEMEDS) online platform, which aims to promote price transparency among contributing countries.

Thank you.